| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
87 |
| Employees |
355 |
| Revenues (TTM) (Millions $) |
175 |
| Net Income (TTM) (Millions $) |
-190 |
| Cash Flow (TTM) (Millions $) |
-23 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Deciphera Pharmaceuticals Inc is a biopharmaceutical company that is focused on discovering, developing, and commercializing kinase inhibitor therapies for the treatment of patients with cancer. The company was established in 2003 and is based in Waltham, Massachusetts.
The core technology of Deciphera Pharmaceuticals is its proprietary kinase switch control inhibitor platform (KSCI). This technology enables the company to design highly selective inhibitors that target specific kinases and to optimize the molecules with respect to potency, safety, and pharmacokinetics.
The company's lead product candidate is Ripretinib (DCC-2618), an inhibitor of KIT and PDGFRe kinases that is being evaluated for the treatment of patients with gastrointestinal stromal tumors (GISTs). GISTs are rare cancerous tumors that arise in the digestive tract and account for approximately 1% of all gastrointestinal tumors.
In addition to Ripretinib, Deciphera Pharmaceuticals has a pipeline of early-stage product candidates that are being developed for the treatment of a variety of solid tumor indications. These include inhibitors of kinases such as FGFR, CSF1R, and VEGFR.
Deciphera Pharmaceuticals has collaborated with several pharmaceutical companies, including Eli Lilly and Company, Sanofi, and Takeda Pharmaceutical Company Limited, to develop and commercialize its product candidates. The company has also entered into licensing agreements with other companies to further develop its KSCI platform and expand its product portfolio.
The company has received several awards and recognitions for its innovative technology and drug development efforts. In 2019, Deciphera Pharmaceuticals was named one of the top 50 most innovative companies in the world by Fast Company. The company is also listed on the NASDAQ Global Select Market under the ticker symbol "DCPH."
Company Address: 200 Smith Street Waltham 2451 MA
Company Phone Number: 209-6400 Stock Exchange / Ticker: NASDAQ DCPH
|
%
2.08%